// App-Quantinova.ai

: A phase 1b/2, open-label study of amivantamab monotherapy or in combination with standard-of-care chemotherapy in participants with advanced or metastatic colorectal cancer.

Researchers

Presenter

  • Paul Eliezer Oberstein

Principal Investigators

  • Cathy Eng

  • Eric Van Cutsem

  • Elena Elez

  • Michel Ducreux

  • Sejal Patel

  • Dona Pang

  • Leann Milford

  • Ryota Iwasawa

  • Robert W. Schnepp

  • Roland Knoblauch

  • Meena Thayu

Medical Centers

  • NYU Langone Health, New York, NY

  • Janssen Pharm KK, Suginami-Ku, Japan

  • Gustave Roussy, Arcueil, France

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Vanderbilt-Ingram Cancer Center, Nashville, TN

  • ICON plc, Blue Bell, PA

  • University of Leuven, KUL, Leuven, Belgium

  • Janssen-Cil, Macquarie Park, Australia

  • Janssen R&D,, London, United Kingdom,

  • Janssen, Spring House, PA

Locations

  • United Kingdom

  • Australia

  • United States

  • Belgium

  • Spain

  • Japan

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Colorectal Cancer

  • Solid malignancies

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

  • KRAS proto-oncogene, GTPase

  • GTPase Nras

Drug/Treatment

  • Oxaliplatin

  • Irinotecan

  • mFOLFOX6

  • FOLFIRI

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

  • Cohort

Phase

  • I

Study Id's

  • NCT05379595

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved